公司管理团队将于北京时间2026年2月26日（星期四）晚上9时举行业绩电话会议 OpenExchange非共价BTK抑制剂pirto对泽布替尼影响有限，我们持续看好泽布替尼业绩兑现 横向比较pirto vs ibru数据：1）从疗效上，泽布替尼中位随访时间42.5mo，PFS HR为0.69；而pirto在中位随访时间为 18.2mo下，PF 【国泰海通医药】百济神州重点推荐：看好泽布替尼业绩兑现+年内实体瘤进展 公司管理团队将于北京时间2026年2月26日（星期四）晚上9时举行业绩电话会议 OpenExchange非共价BTK抑制剂pirto对泽布替尼影响有限，我们持续看好泽布替尼业绩兑现 横向比较pirto vs ibru数据：1）从疗效上，泽布替尼中位随访时间42.5mo，PFS HR为0.69；而pirto在中位随访时间为 18.2mo下，PFS HR为0.845；2）从安全性上看，zanu在多个临床主要的副作用发生率均肩对肩下发生率均优于 pirto。 公司认为从目前数据看，pirto难以撼动CLL用药格局。 【国泰海通医药】百济神州重点推荐：看好泽布替尼业绩兑现+年内实体瘤进展 Soron+Zan ...

Group 1 - Jichuan Pharmaceutical has acquired exclusive commercialization rights for the drug Benvimod Ointment in mainland China, with a total payment not exceeding RMB 1.9 billion (including tax) [1][7] - Benvimod Ointment is the first approved treatment for eczema in children aged 2 and above in China, providing a non-hormonal option for young patients [1][7] - The product is expected to be launched in November 2024 and is currently in the early stages of market expansion [1][7] Group 2 - BeiGene reported a total revenue of USD 5.3 billion for 2025, a 40% increase year-on-year, with significant contributions from its products [2][8] - The company anticipates revenue of USD 6.2 to 6.4 billion for 2026, with GAAP operating profit projected at USD 7 to 8 billion [2][8] Group 3 - Charles River Laboratories announced the divestiture of its entire CDMO business and part of its early discovery services in Europe, generating approximately USD 2.87 billion in revenue last year [3][9] - The divested CDMO business, which focuses on gene therapy production, is expected to be sold to GI Partners and IQVIA [3][9] Group 4 - Zai Lab reported a total revenue of USD 127.6 million for Q4 2025, a 17% increase year-on-year, and an annual revenue of USD 460.2 million, a 15% increase [4][10] - The company is advancing its pipeline with several promising products expected to enter registration studies by the end of 2026 [4][10] Group 5 - Baillie Gifford's ADC drug, Iza-bren, achieved positive results in a Phase III trial for triple-negative breast cancer, marking a significant milestone for the drug [5][10] - The trial demonstrated a significant extension in both progression-free survival (PFS) and overall survival (OS) [5][10] Group 6 - Tianchen Biopharmaceuticals is preparing for an IPO on the Hong Kong Stock Exchange, having raised significant funding in recent years [6][11] - The company focuses on developing innovative drugs for allergic and autoimmune diseases, with key products currently in clinical development [6][11] Group 7 - Zhixiang Jintai reported a total revenue of approximately RMB 231 million for 2025, a staggering increase of 666.65% year-on-year, despite significant losses [12][13] - The company experienced a decline in operating profit and net profit compared to the previous year [12][13]

①美国三大股指收盘涨跌不一，道指涨0.03%报49499.2点，标普500指数跌0.54%报6908.86点，纳指跌 1.18%报22878.38点； ②大型科技股多数下跌，英伟达跌超5%，创去年4月16日以来最大单日跌幅；英特尔跌逾3%，特斯拉 跌超2%，谷歌、亚马逊跌超1%，苹果小幅下跌；奈飞涨超2%，微软、Meta小幅上涨； ③热门中概股多数下跌，盛美半导体跌超16%，百济神州跌逾8%，万国数据跌超7%，名创优品跌近 6%，百度集团跌超5%，贝壳跌逾5%；涨幅方面，大健云仓涨超33%，玉柴国际涨逾6%，希尔威金属 矿业涨超4%，小马智行涨逾4%； ④欧洲三大股指收盘全线上涨，德国DAX指数涨0.45%报25289.02点，法国CAC40指数涨0.72%报 8620.93点，英国富时100指数涨0.37%报10846.7点； ⑤国际贵金属期货普遍收跌，COMEX黄金期货跌0.47%报5201.50美元/盎司，COMEX白银期货跌3.02% 报88.86美元/盎司； ⑥美油主力合约收涨0.08%，报65.47美元/桶；布油主力合约涨0.48%，报71.03美元/桶； ⑦纽约尾盘，美元指数涨0.13%报97. ...

资讯日报：美伊日内瓦会谈取得进展 股票市场概览 港股市场表现 美股市场表现 2026 年 2 月 27 日 资讯日报 海外市场主要股市上日表现 | 指数 | 收盘价 | 日常跌 | 間微跌 | 年初至今 湖铁 | | --- | --- | --- | --- | --- | | | | (%) | (%) | | | | | | | (%) | | 恒生指数 | 26.381 | (1.44) | (0.12) | 2.93 | | 恒生科技 | 5.109 | (2.87) | (1.96) | (7.37) | | 恒生国企 | 8.814 | (2.44) | (1.62) | (1.12) | | 上证指数 | 4.147 | (0.01) | 1.58 | 4.48 | | 日经225 | 58.583 | 0.29 | 3.39 | 16.71 | | 新加坡海峡 | 5.008 | (0.87) | (1.06) | 0.00 | | 标普500 | 6.946 | (0.54) | (0.01) | 0.93 | | 纳斯达克 | 23.152 | (1.18) | (0.03) | (1. ...

期指：节后开门红效应转弱，震荡走势 毛磊 投资咨询从业资格号：Z0011222 maolei@gtht.com 金 融 期 货 研 究 2026 年 2 月 27 日 请务必阅读正文之后的免责条款部分 1 国 泰 君 安 期 货 研 究 期货研究 【期指期现数据跟踪】 期指数据 | | 收盘价 | 涨跌幅% | 基差 | 成交额-亿 | 成交量 | 变动 | 持仓量 | 变动 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 沪深300 | 4726.9 | ↓0.19 | | 5998.5 | | | | | | IF2603 | 4712.2 | ↓0.40 | -14.67 | 790.2 | 55890 | ↓13915 | 145477 | ↓13028 | | IF2604 | 4706.6 | ↓0.40 | -20.27 | 38.4 | 2720 | ↓67 | 3092 | ↑365 | | IF2606 | 4671.2 | ↓0.52 | -55.67 | 268.7 | 19159 | ↓6155 | 85856 ...

2月27日，A股三大股指集体低开，其中沪指跌0.43%报4128.9点，深成指跌0.89%报14375.25点，创业板 指跌1.23%报3303.98点，科创50指数跌1.2%报1468.08点；CPO概念（核心股）多股低开，特发信息竞 价逼近跌停，明阳电路开跌7%，天孚通信开跌5.8%，长盈通、长飞光纤等跟跌；存储芯片板块低开， 盛美上海跌超5%，三孚股份跌超3%，生益科技、通富微电等跟跌；钛白粉（核心股）概念盘初走强， 金浦钛业涨停，东华科技涨超3%，惠云钛业、鲁北化工（核心股）等跟涨；量子科技概念逆势活跃， 格尔软件涨停，科大国创、富士达、神州信息、德美化工跟涨。 盘面上，市场焦点股豫能控股（6板）高开5.19%，光纤光缆概念股法尔胜（4板）低开2.37%，化工 （核心股）板块澄星股份（3板）低开3.24%、金正大（3板）高开4.96%，算力（核心股）工程概念股 华胜天成（4天2板）平开，有色金属（核心股）板块云南锗业（2板）高开0.61%、章源钨业（6天4 板）高开4.42%。 公司动态：业绩与布局齐飞 招商轮船受市场供需结构影响，国际油轮市场高涨，干散货船型市场需求强劲。 沪电股份处于筹划重大事项阶 ...

Core Insights - The introduction of PD-1 inhibitors in 2014 marked a significant turning point in the fight against cancer, with Bristol-Myers Squibb's Opdivo and Merck's Keytruda leading the charge in immunotherapy [1][3] - The competition between Opdivo and Keytruda has evolved over the years, with Keytruda ultimately becoming the top-selling drug globally by 2024 [21][22] Historical Context - The history of cancer immunotherapy began with William Coley's discovery in the late 19th century, which was followed by a long period of stagnation until the late 20th century when key immune cells were identified [4] - The discoveries of James Allison and Tasuku Honjo regarding CTLA-4 and PD-1, respectively, laid the groundwork for the development of PD-1 inhibitors [5][10] Drug Development - Opdivo was developed with strong backing from Bristol-Myers Squibb after acquiring Medarex in 2009, leading to its approval in Japan in 2014 [12] - Keytruda's development faced initial setbacks but was revitalized by Merck's strategic decision to conduct an unprecedented "super I phase" trial, leading to its approval shortly after Opdivo [14][15][16] Market Dynamics - In 2016, a critical competition occurred between Opdivo and Keytruda in the non-small cell lung cancer (NSCLC) market, which is the largest segment in oncology [17] - BMS's failure in the CheckMate-026 trial led to a significant drop in Opdivo's market position, while Merck's more selective approach in the KEYNOTE-024 trial resulted in Keytruda's success [18][19][20] Sales Performance - By 2024, Keytruda's sales reached $29.5 billion, marking an 18% increase and solidifying its position as the top-selling drug globally [21] - Opdivo, while still a major player, saw its sales decline but remained above the $10 billion mark, maintaining its status as a heavyweight in the market [22][23] Competitive Landscape - The global PD-1 inhibitor market is highly competitive, with 527 candidates in development as of early 2025, including 20 approved drugs [26][29] - In China, the market is characterized by intense competition among local manufacturers, with significant price reductions due to national healthcare negotiations [30][31] Future Outlook - Keytruda's core patent is expected to expire in 2028, potentially leading to a significant drop in sales as biosimilars enter the market [32] - A new challenger, Ivonescimab, has shown superior efficacy compared to Keytruda in clinical trials, indicating a shift towards dual-target therapies in cancer treatment [33][35]

【回购/增减持】 小米集团-W(01810)2月26日耗资约9999.68万港元回购283.22万股 吉利汽车(00175)2月26日斥资6311.8万港元回购384.1万股 【重大事项】 德视佳(01846)拟斥巨资收购荷兰屈光手术领军企业FYEO Europe B.V. 2月27日复牌 美格智能(03268)于2月27日至3月5日招股，拟全球发售3500万股H股 埃斯顿(02715)于2月27日至3月4日招股，拟全球发售9678万股H股 兆威机电(02692)于2月27日至3月4日招股，预计3月9日上市 优乐赛共享(02649)于2月27日至3月4日招股，拟全球发售2033.6万股H股 蔚来-SW(09866)子公司就22.57亿元人民币投资订立最终协议 贪玩(09890)拿下《天龙八部2：飞龙战天》双端独家运营权并入股游戏研发商上海阅龙 贝康医疗-B(02170)：Geri胚胎培养液(Gems胚胎培养液系列产品之一)获国家药监局颁发医疗器械注册证 周大福创建(00659)发布中期业绩 股东应占溢利按年增长15%至13.343亿港元 百济神州(06160)2025年业绩强劲增长 经调整净利润约9.18亿美 ...

| < W | 英伟达(NVIDIA) | | | --- | --- | --- | | | NVDA.O | | | 184.900 | 量 3.60亿 股本 243亿 市盈 ™ 37.4 万得 | | | -10.660 --5.45% | 盘口 换 1.48% 市值14.5万亿 市净＂ 28.56 | | | ■ ▼ | 更多 向 五日 日K 周Ｋ 月Ｋ | | | 叠加 | 均价： 187.359 ೈ □ | | | 206.738 | 5.72% 卖1 184.930 | | | | 买1 184.880 | 50 | | | 16:00 184.920 100 | | | 195.560 | 0.000 16.00 184.920 | 27 | | | 16:00 184.920 | 20 | | | 16:00 184.920 | 20 | | | 16:00 184.920 | 25 | | 184 | 16:00 184.920 | 50 | 消息面上，英伟达近日公布了其2025财年第四季度财报，英伟达数据中心业务收入同比增长75%，达623亿美元，但约一半销售额来自超大规模客户，引 发需 ...

《科创板日报》2月27日讯，今日科创板早报主要内容有：一夜蒸发超万亿元，英伟达创10个月最大单 日跌幅；谷歌推出最新图像模型Nano Banana 2；百度集团第四季度营收327.4亿元；百济神州2025年净 利润14.22亿，同比扭亏为盈。 《科创板日报》主播小K为您播报。 【市场动态】 中国AI调用量首超美国 四款大模型霸榜全球前五 全球最大的AI模型API聚合平台OpenRouter数据显示，9日-15日这周，中国模型以4.12万亿Token的调用 量，首次超过同期美国模型的2.94万亿Token。16日-22日这周，中国模型的周调用量进一步冲高至5.16 万亿Token，三周大涨127%，而同期美国模型调用量跌至2.7万亿Token。平台调用量排名前五的模型 中，有四款来自中国厂商，分别为MiniMax的M2.5、月之暗面的Kimi K2.5、智谱的GLM-5以及 DeepSeek的V3.2。这四款模型合计贡献了Top5总调用量的85.7%。值得注意的是，该平台的用户主要由 海外开发者构成，其中美国用户占比高达47.17%，而中国开发者仅占6.01%，这使得其榜单数据更能客 观反映中国AI模型在全球范 ...